BDC-4182

· Bolt Biotherapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BDC-4182, covering 2026-01-27 to 2026-01-27. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer [Phase 1, Phase 2]

See pricing